Anal Cancer
Conditions
Keywords
Radiotherapy, Anal cancer, IMRT
Brief summary
The purpose of this study is to evaluate the efficacy and adverse events of intensity modulated radiation therapy (IMRT) concurrent with chemotherapy for anal squamous carcinoma. All enrolled anal squamous carcinoma patients are intented to receive IMRT concurrent with Capecitabine + mitomycin ± cetuximab targeted therapy.
Interventions
RADIATIONChemo-radiotherapy with IMRT technique
IMRT radiation technique; 50.4-54Gy/25F
DRUGCapecitabine
Capecitabine 825mg/m2 PO BID
DRUGMitomycin C
Mitomycin C 10mg/m2 D1,29 iv
Sponsors
Chinese Academy of Medical Sciences
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* CT/MRI diagnosed stage cT1-4N0-3; * Histologically confirmed anal squamous carcinoma; * KPS \>= 70 * Adequate organ function; * No previous radiotherapy or chemotherapy; * No surgery.
Exclusion criteria
* Previous malignant cancer history; * Allegic to 5-fu or MMC
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response rate | 8 weeks after IMRT | To evaluate response rate of IMRT with chemotherapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events | from start of IMRT to 8 weeks after IMRT | To assess the adverse events of IMRT with chemotherapy |
Countries
China
Contacts
Primary ContactNing Li, MD
Outcome results
None listed